My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every time.
Start Systematic Stock Investing …in less than a minute.
BSE: 532649 | NSE: NECLIFE | Pharmaceuticals & Drugs | Small Cap
1. Is Nectar Lifesciences Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Nectar Lifesciences Ltd is a average quality company.
2. Is Nectar Lifesciences Ltd undervalued or overvalued?
The key valuation ratios of Nectar Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
3. Is Nectar Lifesciences Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Nectar Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |||
| ROCE % ⓘ | 9.3% | 9% | 8.4% | 7.4% | 7.2% | 6.8% | 7.5% | 6% | 1.2% | 3.8% | - | ||
| Value Creation Index ⓘ | -0.3 | -0.4 | -0.4 | -0.5 | -0.5 | -0.5 | -0.5 | -0.6 | -0.9 | -0.7 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 1,626 | 1,638 | 1,644 | 1,676 | 1,643 | 1,876 | 2,785 | 2,363 | 1,542 | 1,668 | 1,711 | ||
| YoY Gr. Rt. % | - | 0.7% | 0.3% | 2% | -2% | 14.1% | 48.5% | -15.2% | -34.8% | 8.2% | - | ||
| Adj EPS ⓘ | 3.8 | 2.8 | 3 | 2.4 | 2.4 | 2.3 | 2.1 | 1.3 | -2.5 | 0.8 | 0.1 | ||
| YoY Gr. Rt. % | - | -27.5% | 6.5% | -17.6% | -0.4% | -3.7% | -9% | -37.3% | -285.7% | NA | - | ||
| BVPS (₹) ⓘ | 38.7 | 41.3 | 41.1 | 42.6 | 44.9 | 47.2 | 49.3 | 50.6 | 47.3 | 48.5 | 47.6 | ||
| Adj Net Profit ⓘ | 85.7 | 62.1 | 66.2 | 54.4 | 54.3 | 52.2 | 47.5 | 29.9 | -55.4 | 18.7 | 3 | ||
| Cash Flow from Ops. ⓘ | 361 | 255 | 144 | 169 | 199 | 65.1 | 239 | 286 | 21.3 | 95 | - | ||
| Debt/CF from Ops. ⓘ | 2.4 | 3.4 | 6.4 | 5.7 | 4.4 | 14.7 | 3.8 | 2.7 | 42.4 | 9.1 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 0.3% | 0.3% | -15.7% | 8.2% | ||||||||
| Adj EPS ⓘ | -15.5% | -19.1% | -26.6% | NA | ||||||||
| BVPS ⓘ | 2.5 | 1.5 | -0.5 | 2.5 | ||||||||
| Share Price | 0.5% | -8.5% | 17.6% | -15.8% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | ||
| Return on Equity % ⓘ | 10.4 | 6.9 | 7 | 5.7 | 5.5 | 5.1 | 4.4 | 2.7 | -5 | 1.7 | 0.3 | |
| Op. Profit Mgn % ⓘ | 17.8 | 17.6 | 16.2 | 14.3 | 13.6 | 12.6 | 9.5 | 9.2 | 6.6 | 9.5 | 7.6 | |
| Net Profit Mgn % ⓘ | 5.3 | 3.8 | 4 | 3.3 | 3.3 | 2.8 | 1.7 | 1.3 | -3.6 | 1.1 | 0.2 | |
| Debt to Equity ⓘ | 1 | 0.9 | 1 | 1 | 0.9 | 0.9 | 0.8 | 0.7 | 0.9 | 0.8 | 0.2 | |
| Working Cap Days ⓘ | 251 | 270 | 285 | 298 | 324 | 292 | 206 | 240 | 330 | 288 | 295 | |
| Cash Conv. Cycle ⓘ | 133 | 125 | 134 | 142 | 153 | 133 | 104 | 115 | 132 | 108 | 77 | |
Return on Equity has increased versus last 3 years average to 0.30%
Debt to equity has declined versus last 3 years average to 0.79
Sales growth is good in last 4 quarters at 16.28%
Sales growth has been subdued in last 3 years -15.70%
Net Profit has been subdued in last 3 years -26.55%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.1 | 0.1 |
| TTM Sales (₹ Cr.) | 1,711 | 1,711 |
| BVPS (₹.) ⓘ | 47.6 | 47.7 |
| Reserves (₹ Cr.) ⓘ | 1,046 | 1,047 |
| P/BV ⓘ | 0.44 | 0.44 |
| PE ⓘ | 165.57 | 167.92 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 19.50 / 38.95 |
| All Time Low / High (₹) | 7.20 / 60.90 |
| Market Cap (₹ Cr.) | 473 |
| Equity (₹ Cr.) | 22.4 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 37.3 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
Nectar Lifesciences Ltd. (NLL) is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. It has emerged as top ranked organization amongst midsized Pharmaceutical companies in India as per “Fortune Next 500” 2017 & is among top 40 fore runners of the Bio-Pharmaceutical industry in Asia-Pacific Region as per “Bio-Spectrum Asia Pacific” 2016 besides being one of the top amongst Indian API manufacturers.
The company has transformed itself from being a small Domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. It currently has a strong hold of API & Formulation business in many countries of the world with various State of Art manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels.
Business area of the company
The company has developed fully integrated sustainable production systems to manufacture high quality Cephalosporin intermediates, - Active Pharmaceuticals ingredients (APIs) and Finished Dosage Formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and over many countries worldwide.
Business segments
Certifications
